Important note

This AI stock analysis for Moderna is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!


Moderna - AI Stock Analysis

Analysis generated January 28, 2025

Moderna, Inc. is a biotechnology company primarily known for its development of mRNA technology, which has been a cornerstone in the creation of its COVID-19 vaccine. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company has rapidly emerged as a leader in vaccine technology. Using its proprietary mRNA platform, Moderna aims to develop vaccines and treatments for a range of diseases, including infectious diseases, immuno-oncology, and rare diseases.

Fundamental Analysis

Moderna reported a revenue of $1.85 billion in the last quarter. This represents an extraordinary increase of 746.58% compared to the previous quarter. Year-over-year, revenue increased by 3.11%, indicating consistent growth. Net income for the last quarter was $13 million, showing an increase of 101.02% from the previous quarter and 100.36% compared to the same quarter last year, further signaling positive impact on profitability.

The EBITDA for the last quarter was $18 million, marking a 98.64% increase from the previous quarter and a 98.98% increase from the same quarter last year. The current Price-to-Earnings (P/E) ratio is 24.73, which aligns within industry norms, suggesting that the stock is neither overvalued nor undervalued. Notably, some company insiders have been selling their stock recently, which can be seen as a bearish signal.

Technical Analysis

Today's stock price is $41.65, an increase of 3.79% compared to a month ago, reflecting a positive short-term trend. However, the stock price has decreased by 60.27% over the past year, which might raise concerns about long-term performance. The Simple Moving Average over 10 days (SMA10) is at 39.24, up from the previous SMA10 of 38.49, indicating potential continued upward movement. The Relative Strength Index (RSI) is 21.8, suggesting that the stock is in an oversold condition and may experience a bullish reversal.

Alternative Data Analysis

Moderna's job postings have decreased by 48% over the past few months, now totaling 134 open positions. This reduction may indicate efforts to cut costs or improve margins, which may not be ideal for a growth-oriented company. Employee sentiment is neutral, reflecting neither high optimism nor low morale.

Website traffic to Moderna's webpage is estimated at 280,000 visitors, a 10% decrease over the last few months, signaling potential diminishing customer interest. Twitter followers, a proxy for customer engagement, have reduced by 2% to 150,000. According to AltIndex, an AI score that predicts stock performance, Moderna has a score of 38, indicating a sell signal.

Conclusion and Recommendation

In conclusion, Moderna has demonstrated impressive growth metrics in terms of revenue, net income, and EBITDA over the last quarter and year-over-year. However, insider stock selling, declining website traffic, fewer job postings, and a decrease in social media engagement raise flags about future growth and customer sentiment. The current RSI indicates a potential opportunity for bullish reversal, while the AI score of 38 suggests caution.

Based on the combined analysis, the recommendation is to approach Moderna's stock with caution. While there are signs of robust financial growth, the various bearish indicators may signal underlying issues that require careful consideration.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2025 AltIndex. All rights reserved.